Both compounds used as sole therapy yielded a modest differentiation response, but in combination, exerted a more potent response and reduced viability in the MYCN-amplified NB cells (Duffy et al., 2017), thereby signifying the importance of using combination therapy in MYCN-amplified, high-risk NB patients to reach better clinical outcomes. Here, MYCN is linked to neuroblastoma.